Efficacy of Pasteur hepatitis B vaccine in medical students

Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students

A group of 92 medical students were immunized with a commercial recombinant hepatitis B vaccine (Engerix B). Antibody responses were determined and compared with those to plasma-derived Pasteur vaccine, obtained in 1986. Antibody concentrations were significantly higher in the group given recombinant vaccine, therefore this vaccine has superior immunogenicity and probably confers extended duration of protection.

Low-dose intradermal vaccination of medical and dental students

In 454 medical and dental students who were vaccinated against hepatitis B by means of a low dose (0.1 mL) of serum-derived vaccine, seroconversion rates of 27%, 70% and 89% were obtained after the first, second and third doses, respectively. These figures are comparable with the results that have been reported for the conventional intramuscular schedule, as were the final antibody titres. A fourth intradermal dose boosted the percentage of students who were protected from 82% to 87%. There was a significant variation in the response to different batches of vaccine. This study shows that the low-dose intradermal method is practicable and effective and can be used to achieve great economy in hepatitis B vaccination programmes. The possibility of adding hepatitis B to the present formula of triple antigen should be investigated as a way of extending hepatitis B vaccination to all infants in our community.